Bli medlem
Bli medlem

Du är här


Saniona: Redeye: Saniona - Early Christmas gift from Mexico

Saniona announced yesterday that the tesofensine phase III trial met
its primary and secondary endpoints. We have updated our valuation
model accordingly. The news has ripple effects for other Saniona
programs which comprise tesofensine.

Read more in the research update by Anders Hedlund:

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.